|  |  |  |
| --- | --- | --- |
| **A3. Drug / Compound “CV”** | **Current information** | **Information needed or work to be done** |
| **Drug name, alternative name** |  |  |
| Drug class |  |  |
| Intervention code |  |  |
| Origin |  |  |
| Generic? |  |  |
|  |  |  |
| **Safety record** |  |  |
| Toxicology studies |  |  |
| Tested in humans |  |  |
| Side effects |  |  |
| Possible off target effects |  |  |
| Contraindications |  |  |
|  |  |  |
| Efficacy in models |  |  |
| Mode of delivery |  |  |
| Dose |  |  |
|  |  |  |
| **Owner/owners** |  |  |
| IP landscape/patent duration |  |  |
| Delivery mechanism |  |  |
| License status |  |  |
|  |  |  |
| Target molecular pathway |  |  |
| Selectivity |  |  |
| Protective/restorative |  |  |
| Monitoring requirements / known side effects |  |  |
| Tested/Used for which conditions |  |  |
| PK, PD, ADME |  |  |
| CNS penetration |  |  |
|  |  |  |
| **Steps needed to move it to clinic** |  |  |
| Preclinical work? |  |  |
| Which models to use? |  |  |
| Existing trials (Pub Med) |  |  |
| Trial size |  |  |
| Patient group and heterogeneity |  |  |
| Drugs for comparison? |  |  |
| Regulatory concerns |  |  |
| Funding required |  |  |
| Parkinson’s specialists to involve |  |  |
|  Anticipated time to clinic |  |  |
| Estimated cost to clinic |  |  |